The effective anti-tumor immune response induced by synthetic CpG-ODN agonists of TLR9 in preclinic and clinical studies with anti-PD-1 antibody therapy revealed the critical role IFN-γ signaling for anti-PD-1 response23. The gene discussed is TLR9; the disease is neoplasm.